Organisation paid for research Program year 2021 Source: CMS Open Payments

US Oncology P A

Neither a doctor nor a teaching hospital

Research payments

$247,633

10 payments

Through program year 2021, US Oncology P A is reported as receiving $247,633 in research payments, across 10 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$239,070	6
2020	Research	$1,862	2
2019	Research	$6,702	2

Breakdown

Who paid Research payments · program years 2019–2021

Novartis Pharmaceuticals Corporation $247,633 10 payments

Studies the money was for Research payments · program years 2019–2021

An Open Label, Multi-Center Phase Iiib Study of Asciminib (Abl001) Monotherapy in Patients With Chronic Myelogenous Leukemia on Chronic Phase (Cml-Cp) Previously Treated With at Least 2 Prior Tkis (Tyrosine Kinase Inhibitors) $125,360 1 payment
A Phase III Randomized Study to Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Olaparib in Patients With No Germline Brca Mutation Detected, Platinum-Resistant Or Refractory, High Grade Serous Ovarian Cancer $57,385 1 payment
Epik-B4: A Phase II, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (Byl719) in Combination With Fulvestrant in Participants With HR+, Her2-, Advanced Breast Cancer With A Pik3ca Mutation Following Progression Ofter Endocrine-Based Therapy $40,881 1 payment
Phase II Open Label Study of Ofatumumab and Bendamustine Followed By Maintenance Ofatumumab for Indolent Bcell Nonhodgkins Lymphoma BNHL Which Has Relapsed After Rituximab Therapy $15,360 2 payments
Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab VS Placebo in Adjuvant Setting $5,665 3 payments
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Nab-Paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha (Pik3ca) Mutation Or Phosphatase and Tensin Homolog Protein (Pten) Loss Without Pik3ca Mutation $2,892 1 payment
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Nab-Paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3- $90 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.